in Health care
Lower-Dose Regimens of Exemestane Effective in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer
According to research reported in JAMA Oncology, based on findings from a phase IIb trial, 25 mg exemestane thrice weekly is noninferior to the standard dosing of 25 mg once daily pertaining to reduction of serum estradiol among postmenopausal patients with stage 0 to II estrogen receptor (ER)-positive breast cancer. Minimal effective dose is an […] More
